Mayo Clinic Proceedings Home

Regional and Systemic Strategies for Metastatic Malignant Melanoma

      Malignant melanoma is no longer a rare neoplasm. Recreational exposure to sunlight is undoubtedly an etiologic factor. Among all cancers, its rate of increase is exceeded only by that of bronchogenic carcinoma. Before administration of systemic therapy, histologic confirmation of the diagnosis and assessment of both the relative medical fitness of the patient and the available psychosocial support are important. Chemotherapeutic and interferon-α regimens may offer transient reprieve in 15 to 20% of patients but yield few long-term survivors. Other biologic response modifiers, such as tumor necrosis factor and interleukin 2, are promising but without established consistent efficacy. Postoperative systemic treatment programs for patients at risk for disseminated disease are of no proven benefit in randomized trials and cannot be endorsed outside of the context of a clinical trial. Radiation therapy may provide useful palliation, especially with a fraction of 400 cGy rather than the more traditional dose of 200 cGy/fraction. Selected patients with metastatic disease may benefit from surgical resection, but residual disease after attempted extirpation is usually associated with prolonged disability.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Balch CM Milton GW Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. JB Lippincott Company, Philadelphia1985
        • Nathanson L
        • Kaufman SD
        • Carey RW
        Vinblastine-bleomycin-platinum (VBD): a high response rate regimen in metastatic melanoma (abstract).
        Proc Annu Meet Am Assoc Cancer Res Am Soc Clin Oncol. 1980; 21: 479
        • Nathanson L
        • Kaufman SD
        • Carey RW
        Vinblastine, infusion, bleomycin, and cis-dichlorodiammine-platinum chemotherapy in metastatic melanoma.
        Cancer. 1981; 48: 1290-1294
        • Creagan ET
        • Ahmann DL
        • Schutt AJ
        • Green SJ
        Phase II study of the combination of vinblastine, bleomycin, and cisplatin in advanced malignant melanoma.
        Cancer Treat Rep. 1982; 66: 567-569
        • Luikart SD
        • Kennealey GT
        • Kirkwood JM
        Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma.
        J Clin Oncol. 1984; 2: 164-168
        • Carmo-Pereira J
        • Costa FO
        • Henriques E
        Combination cytotoxic chemotherapy with procarbazine, vincristine, and lomustine (POC) in disseminated malignant melanoma: 8 years'follow-up.
        Cancer Treat Rep. 1984; 68: 1211-1214
        • Kessinger A
        High-dose chemotherapy with autologous marrow transplantation for malignant melanoma.
        J Am Acad Dermatol. 1985; 12: 337-343
        • Ghussen F
        • Krüger I
        • Groth W
        • Stützer H
        The role of regional hyperthermic cytostatic perfusion in the treatment of extremity melanoma.
        Cancer. 1988; 61: 654-659
        • Cumberlin R
        • De Moss E
        • Lassus M
        • Friedman M
        Isolation perfusion for malignant melanoma of the extremity: a review.
        J Clin Oncol. 1985; 3: 1022-1031
        • Day Jr, CL
        • Lew RA
        • Mihm Jr, MC
        • Harris MN
        • Kopf AW
        • Sober AJ
        • Fitzpatrick TB
        The natural break points for primary-tumor thickness in clinical stage I melanoma (letter to the editor).
        N Engl J Med. 1981; 305: 1155
        • Balch CM
        The role of elective lymph node dissection in melanoma: rationale, results, and controversies.
        J Clin Oncol. 1988; 6: 163-172
        • Cady B
        “Prophylactic” lymph node dissection in melanoma: does it help? (editorial).
        J Clin Oncol. 1988; 6: 2-4
        • Hersey P
        • Balch CM
        Current status and future prospects for adjuvant therapy of melanoma.
        Aust N Z J Surg. 1984; 54: 303-315
        • Koh HK
        • Sober AJ
        • Harmon DC
        • Lew RA
        • Carey RW
        Adjuvant therapy of cutaneous malignant melanoma: a critical review.
        Med Pediatr Oncol. 1985; 13: 244-260
        • Quirt I
        • Shelley W
        • Bodurtha A
        • McCulloch P
        • McPherson A
        • Paterson A
        • Prentice R
        • Silver H
        • Willan A
        • Wilson K
        Adjuvant levamisole improves survival and disease-free survival in patients with poor prognosis malignant melanoma (abstract).
        Proc Annu Meet Am Soc Clin Oncol. 1986; 5: 130
        • Herberman RB
        Effects of biological response modifiers on effector cells with cytotoxic activity against tumors.
        Semin Oncol. 1986; 13: 195-199
        • Creagan ET
        • Ahmann DL
        • Frytak S
        • Long HJ
        • Chang MN
        • Itri LM
        Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients.
        Cancer Treat Rep. 1986; 70: 619-624
        • Creagan ET
        • Ahmann DL
        • Frytak S
        • Long HJ
        • Itri LM
        Recombinant leukocyte A interferon (rIFN-αA) in the treatment of disseminated malignant melanoma: analysis of complete and long-term responding patients.
        Cancer. 1986; 58: 2576-2578
        • Spiegel RJ
        Clinical overview of alpha interferon: studies and future directions.
        Cancer. 1987; 59: 626-631
        • Creagan ET
        • Kovach JS
        • Long HJ
        • Richardson RL
        Phase I study of recombinant leukocyte A human interferon combined with BCNU in selected patients with advanced cancer.
        J Clin Oncol. 1986; 4: 408-413
        • Creagan ET
        • Long HJ
        • Frytak S
        • Moertel CG
        Recombinant leukocyte A interferon with doxorubicin: a phase I study in advanced solid neoplasms and implications for hepatocellular carcinoma.
        Cancer. 1988; 61: 19-22
        • Rosenberg SA
        • Lotze MT
        • Muul LM
        • Chang AE
        • Avis FP
        • Leitman S
        • Linehan WM
        • Robertson CN
        • Lee RE
        • Rubin JT
        • Seipp CA
        • Simpson CG
        • White DE
        A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
        N Engl J Med. 1987; 316: 889-897
        • Houghton AN
        • Brooks H
        • Cote RJ
        • Taormina MC
        • Oettgen HF
        • Old LJ
        Detection of cell surface and intracellular antigens by human monoclonal antibodies: hybrid cell lines derived from lymphocytes of patients with malignant melanoma.
        J Exp Med. 1983; 158: 53-65
        • Morton RF
        • Creagan ET
        • Cullinan SA
        • Mailliard JA
        • Ebbert L
        • Veeder MH
        • Chang M
        Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-l-aspartate (NSC-224131) plus l-alanosine (NSC-153353) in advanced malignant melanoma.
        J Clin Oncol. 1987; 5: 1078-1082
        • Overgaard J
        The role of radiotherapy in recurrent and metastatic malignant melanoma: a clinical radiobiological study.
        Int J Radiat Oncol Biol Phys. 1986; 12: 867-872
        • Ziegler JC
        • Cooper JS
        Brain metastases from malignant melanoma: conventional vs. high-dose-per-fraction radiotherapy.
        Int J Radiat Oncol Biol Phys. 1986; 12: 1839-1842
        • Greene MH
        • Clark Jr, WH
        • Tucker MA
        • Elder DE
        • Kraemer KH
        • Guerry IV, D
        • Witmer WK
        • Thompson J
        • Matozzo I
        • Fraser MC
        Acquired precursors of cutaneous malignant melanoma: the familial dysplastic nevus syndrome.
        N Engl J Med. 1985; 312: 91-97
        • Greene MH
        • Clark Jr, WH
        • Tucker MA
        • Kraemer KH
        • Elder DE
        • Fraser MC
        High risk of malignant melanoma in melanoma-prone families with dysplastic nevi.
        Ann Intern Med. 1985; 102: 458-465
        • Elder DE
        • Greene MH
        • Guerry IV, D
        • Kraemer KH
        • Clark Jr, WH
        The dysplastic nevus syndrome: our definition.
        Am J Dermatopathol. 1982; 4: 455-460
        • Overett TK
        • Shiu MH
        Surgical treatment of distant metastatic melanoma: indications and results.
        Cancer. 1985; 56: 1222-1230
        • Wornom III, IL
        • Soong S-J
        • Urist MM
        • Smith JW
        • McElvein R
        • Balch CM
        Surgery as palliative treatment for distant metastases of melanoma.
        Ann Surg. 1986; 204: 181-185
        • Lopez R
        • Holyoke ED
        • Moore RH
        • Karakousis CP
        Malignant melanoma with unknown primary site.
        J Surg Oncol. 1982; 19: 151-154
        • Cochran AJ
        • Wen D-R
        • Herschman HR
        Occult melanoma in lymph nodes detected by antiserum to S-100 protein.
        Int J Cancer. 1984; 34: 159-163
        • Keipert JA
        Which pigmented moles should be removed in prepubertal-age children? A case for a conservative approach.
        Med J Aust. 1984; 141: 518-520
        • Peters MS
        • Goellner JR
        Spitz naevi and malignant melanomas of childhood and adolescence.
        Histopathology. 1986; 10: 1289-1302
        • Reintgen DS
        • McCarty Jr, KS
        • Vollmer R
        • Cox E
        • Seigler HF
        Malignant melanoma and pregnancy.
        Cancer. 1985; 55: 1340-1344